Aurobindo Pharma receives warning letter from USFDA for API manufacturing facility

21 Jun 2019 Evaluate

Aurobindo Pharma has received a warning letter from the United States Food and Drug Administration (USFDA) relating to its unit XI, active pharmaceutical ingredient (API) manufacturing facility situated at Srikakulam, in the state of Andhra Pradesh. This action follows the earlier inspection of the site by the USFDA in February 2019.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1200.00 -14.65 (-1.21%)
05-Jan-2026 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1733.60
Dr. Reddys Lab 1253.65
Cipla 1518.80
Zydus Lifesciences 920.55
Lupin 2077.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×